Jonathan Rosenberg

2 weeks ago | oncologynewscentral.com | Jonathan Rosenberg |Robert A. Figlin

“For the first 15 years of my career, we had nothing new” in bladder cancer care, said Jonathan E. Rosenberg, MD, chief of the genitourinary oncology service at Memorial Sloan Kettering Cancer Center in New York City. Now, “the pace of change has been dizzying,” he told Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology.

Nov 21, 2024 | cell.com | Habib Hamidi |Yasin Senbabaoglu |Niha Beig |Juliette Roels |Cyrus Manuel |Xiangnan Guan | +26 more

Keywordsurothelial carcinomatranscriptomicsmolecular heterogeneityPD-L1 blockadepatient stratificationdigital pathologyGet full text accessLog in, subscribe or purchase for full access. References1. Ishida, Y. ∙ Agata, Y. ∙ Shibahara, K. ... Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell deathEMBO J. 1992; 11:3887-38952. Tang, J. ∙ Yu, J.X. ∙ Hubbard-Lucey, V.M. ...

Nov 7, 2024 | urotoday.com | Jonathan Rosenberg

Read the Full Video TranscriptAlicia Morgans: Hi, I am so excited to be here today with Professor Jonathan Rosenberg, who is joining me from Memorial Sloan Kettering after a fantastic discussion at ESMO 2024, where he talked about some novel therapies in GU cancers. Thank you so much for joining me today, Jonathan. Why don't you take it away? Jonathan Rosenberg: It's my pleasure to be here. Today I'm going to discuss two abstracts, focusing on first bladder cancer and then urothelial cancer.

Nov 7, 2024 | urotoday.com | Jonathan Rosenberg

Read the Full Video TranscriptAlicia Morgans: Hi, I am so excited to be here today with Professor Jonathan Rosenberg, who is joining me from Memorial Sloan Kettering after a fantastic discussion at ESMO 2024, where he talked about some novel therapies in GU cancers. Thank you so much for joining me today, Jonathan. Why don't you take it away? Jonathan Rosenberg: It's my pleasure to be here. Today I'm going to discuss two abstracts, focusing on first bladder cancer and then urothelial cancer.

Nov 4, 2024 | urotoday.com | Jonathan Rosenberg

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Professor Jonathan Rosenberg, who is joining me from Memorial Sloan Kettering after a wonderful presentation at ESMO 2024, where he gave us an update on EV-103 Cohort A and some five-year outcomes. Thank you so much for being here, and please take it away. Jonathan Rosenberg: Thank you so much, Alicia. It's great to be here to talk and update people about the five-year outcomes.